<DOC>
	<DOCNO>NCT00995995</DOCNO>
	<brief_summary>Carry cost-effectiveness analysis rosiglitazone population line rosiglitazone license use UK cost</brief_summary>
	<brief_title>Evaluation Duration Oral Combination Therapy Type 2 Diabetes , Prior Initiation Insulin UK</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Rosiglitazone Type II Diabetes study Studies without require outcome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>